Eosinophilic Granuloma

Disclaimer: This information is intended for medical professionals and is not a substitute for clinical judgment or professional medical advice. Treatment decisions must always be individualized based on the patient's specific condition, comorbidities, and preferences, in consultation with appropriate specialists. While every effort has been made to ensure accuracy, medical knowledge is constantly evolving, and readers should consult primary sources and current guidelines.

Overview

• Definition: Eosinophilic granuloma (EG) is the most common and often the least aggressive form of Langerhans Cell Histiocytosis (LCH). It is characterized by a focal, clonal proliferation of Langerhans cells, often accompanied by a prominent inflammatory infiltrate including eosinophils, lymphocytes, plasma cells, and macrophages. EG is typically a solitary (unifocal) lytic bone lesion, although rarely, multifocal bone involvement can occur, which still falls under the EG spectrum if other organs are not involved. It can also present as a single soft tissue lesion.
• Epidemiology:
  • Incidence: LCH has an estimated incidence of 1-9 cases per million children per year. EG represents approximately 50-70% of all LCH cases.
  • Age: Primarily affects children and young adults, with a peak incidence between 5-15 years of age. It can occur at any age but is rare in infants and the elderly.
  • Sex: A slight male predominance is often observed (male-to-female ratio approximately 1.5:1 to 2:1).
  • Location: Most commonly affects bones (80-90% of cases), particularly the skull (cranium, mandible), ribs, vertebrae, pelvis, and long bones (femur, humerus). Other sites include skin, lymph nodes, lungs, and central nervous system (CNS), but these are less common as primary EG sites without bone involvement.
• Classification: Eosinophilic Granuloma is considered the unifocal (or multifocal bone-only) form of Langerhans Cell Histiocytosis (LCH). LCH itself is broadly classified by the Histiocyte Society into:
  1. Single System LCH (SS-LCH): Involvement of only one organ system.
     • Single Site: A single lesion (e.g., solitary bone lesion, often referred to as Eosinophilic Granuloma).
     • Multifocal: Multiple lesions within a single organ system (e.g., multiple bone lesions, also falls under the EG spectrum if bone-only).
  2. Multisystem LCH (MS-LCH): Involvement of two or more organ systems.
     • Low-risk organs (LRO): Skin, lymph nodes, bone, pituitary gland, lung.
     • High-risk organs (HRO): Liver, spleen, hematopoietic system (bone marrow), lung in very young children, CNS (excluding pituitary). Eosinophilic granuloma specifically denotes the SS-LCH, single-site or multifocal bone-only presentation.

Pathophysiology

• Mechanism: Eosinophilic granuloma arises from a clonal proliferation of pathological Langerhans cells, which are myeloid dendritic cells derived from hematopoietic stem cells. These cells infiltrate various tissues, leading to local destruction and granuloma formation.
  • Molecular Basis: Approximately 50-60% of LCH cases, including EG, are characterized by activating mutations in the MAPK/ERK pathway. The most common mutation is BRAF V600E, found in about 50% of LCH cases. Other mutations include MAP2K1, ARAF, and NRAS. These mutations lead to constitutive activation of the MAPK pathway, promoting cell proliferation and survival.
  • Cellular Infiltrate: The characteristic lesion consists of a proliferation of pathological Langerhans cells (identified by CD1a, S100, and Langerin/CD207 positivity, and Birbeck granules on electron microscopy) mixed with a reactive inflammatory infiltrate of eosinophils (often prominent, giving the lesion its name), lymphocytes, plasma cells, and macrophages.
  • Bone Destruction: In bone lesions, the Langerhans cells and associated inflammatory cytokines (e.g., TNF-α, IL-1, IL-6) activate osteoclasts, leading to local bone resorption and the characteristic lytic lesions seen on imaging.
• Risk Factors: While the exact etiology is unknown, it is generally considered an acquired condition rather than hereditary. There are no clearly established environmental or genetic risk factors for developing EG, unlike some other cancers. Some theories suggest a dysregulated immune response to an unknown trigger.
• Protective Factors: None currently identified. As EG is not considered preventable in the traditional sense, there are no known protective factors.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Pain: Most common symptom, localized to the affected bone, often worse at night or with activity. Can be dull, aching, or sharp.
  • Swelling/Tenderness: A palpable soft tissue mass or localized tenderness over the affected bone, particularly in superficial locations like the skull or ribs.
  • Pathological Fracture: Can be the presenting symptom, especially in weight-bearing bones or vertebrae, due to significant bone destruction.
  • Functional Impairment: Depending on the location, e.g., limping if in a long bone, vertebral collapse leading to neurological symptoms.
• Early Signs:
  • Localized bone pain, often insidious in onset.
  • Mild, localized swelling or tenderness.
  • In children, unexplained irritability or avoidance of certain movements.
• Advanced Signs: (More common with progressive or atypical presentations, or untreated cases)
  • Severe, persistent pain.
  • Deformity, especially in weight-bearing bones or skull.
  • Neurological deficits: If spinal involvement leads to cord compression (e.g., weakness, paresthesias, bowel/bladder dysfunction).
  • Hearing loss or otorrhea: If temporal bone or mastoid involvement.
  • Proptosis: If orbital involvement.
• Atypical Presentations:
  • Asymptomatic Lesion: Occasionally discovered incidentally on imaging for another reason.
  • Diabetes Insipidus: Rarely, as a manifestation of LCH, but less common with isolated EG. More indicative of pituitary involvement in multisystem LCH.
  • Skin Rash: While common in multisystem LCH (especially in infants), it's rare as the sole presentation of EG.

Physical Examination

• Inspection:
  • Localized swelling, erythema, or asymmetry over the affected bone.
  • Visible deformity if a pathological fracture has occurred (e.g., skull deformity, scoliosis from vertebral collapse).
  • Skin lesions are rare in isolated EG but should prompt suspicion for multisystem LCH.
• Palpation:
  • Localized tenderness directly over the bone lesion is a consistent finding.
  • Palpable mass, which may be firm or fluctuant.
  • Warmth over the affected area may be present due to inflammation.
• Special Tests:
  • Neurological Examination: Essential for any suspected spinal or cranial involvement to detect motor weakness, sensory deficits, or cranial nerve palsies, which would indicate potential spinal cord or brain compression.
  • Range of Motion (ROM) Assessment: For lesions near joints, to assess for pain or restriction.
  • Gait Analysis: For lower extremity lesions.

Diagnostic Approach

History Taking

• Key Questions:
  • Pain characteristics: Location, intensity (0-10 scale), duration, aggravating/alleviating factors, nocturnal pain.
  • Associated symptoms: Swelling, tenderness, fever, weight loss, night sweats (though systemic symptoms are less common in EG).
  • Functional impact: Limitation of movement, limping, weakness, numbness.
  • Past medical history: Any prior similar lesions or other chronic conditions.
  • Family history: Of LCH or other histiocytic disorders (rare).
  • Review of systems: To identify potential involvement of other organ systems (e.g., skin rash, lymphadenopathy, vision changes, polydipsia/polyuria for DI, ear discharge, hearing loss, dental issues).
• Red Flags:
  • Rapidly progressing pain or swelling: May indicate aggressive disease or impending fracture.
  • New neurological deficits: Suggestive of spinal cord compression (e.g., cauda equina syndrome) or cranial nerve involvement, requiring urgent neurosurgical evaluation.
  • Systemic symptoms: Unexplained fever, weight loss, night sweats, fatigue (though uncommon in EG, these warrant investigation for multisystem LCH or other malignancies).
  • Pathological fracture with minimal trauma: Requires prompt assessment and stabilization.

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC) with differential: Usually normal in isolated EG. May show mild leukocytosis with eosinophilia in some cases, but marked cytopenias (anemia, thrombocytopenia) are rare and suggest high-risk multisystem LCH or other bone marrow processes.
  • Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): Can be mildly elevated in active disease, but are non-specific inflammatory markers.
  • Serum chemistry (liver and kidney function tests): Usually normal. Elevated liver enzymes or hypoalbuminemia would raise suspicion for liver involvement in multisystem LCH.
  • Urinalysis and Osmolality: To rule out diabetes insipidus (polydipsia, polyuria, dilute urine), though this is rare in isolated EG.
• Confirmatory:
  • Biopsy of the lesion: This is essential for definitive diagnosis.
    • Histopathology: Shows a characteristic proliferation of Langerhans cells mixed with varying numbers of eosinophils, lymphocytes, plasma cells, and macrophages.
    • Immunohistochemistry (IHC): Pathological Langerhans cells are positive for:
      • CD1a: Highly sensitive marker for Langerhans cells.
      • S100 protein: Sensitive but less specific, as it's also positive in melanoma and neural tumors.
      • Langerin (CD207): Most specific marker for Langerhans cells, as it detects Birbeck granules.
    • Electron Microscopy: Demonstrates Birbeck granules (tennis-racket shaped organelles) within Langerhans cells, if available and needed for challenging cases.
    • Molecular Testing: Recommended for BRAF V600E mutation, especially if systemic therapy is considered for refractory or disseminated disease. This can be done on biopsy tissue.
• Monitoring:
  • Serial CBC, ESR/CRP: To monitor disease activity and response to treatment, especially if observation or systemic therapy is employed.
  • Imaging: Follow-up imaging to assess lesion resolution and detect new lesions (see below).

Imaging

• Recommended:
  • Plain Radiographs (X-rays): Initial imaging modality for suspected bone lesions.
    • Findings: Typically show well-defined, lytic (punched-out) bone lesions with sclerotic margins. Permeative or aggressive features are less common. Can show periosteal reaction and soft tissue swelling. In vertebrae, a "vertebra plana" (pancake vertebra) due to complete collapse is characteristic.
  • Computed Tomography (CT) Scan: Provides better detailed imaging of bone destruction, cortical integrity, and soft tissue extension.
    • Findings: Cortical destruction, soft tissue mass, sometimes intraosseous sequestrum. Excellent for skull, spine, and pelvic lesions.
    • Utility: Useful for surgical planning and assessing spinal canal compromise.
  • Magnetic Resonance Imaging (MRI): Superior for evaluating bone marrow involvement, soft tissue extension, and neural compression.
    • Findings: Lesions are typically hypointense on T1-weighted images and hyperintense on T2-weighted images, with variable contrast enhancement. Defines extent of marrow involvement and relationship to neurovascular structures.
    • Utility: Crucial for spinal lesions to assess cord compression.
  • Bone Scan (Technetium-99m Methylene Diphosphonate, Tc-99m MDP): Used to screen for additional bone lesions, especially if multifocal disease is suspected.
    • Findings: Increased uptake at sites of active bone destruction. However, some EG lesions can be "cold" or have minimal uptake, so a negative bone scan does not completely rule out additional lesions.
  • PET-CT (Positron Emission Tomography-Computed Tomography): With 18F-FDG (fluorodeoxyglucose) can detect metabolically active lesions throughout the body and is highly sensitive for identifying additional sites of disease, particularly for evaluating multifocal LCH. May be considered if there is suspicion of additional lesions not seen on other imaging.
• Advanced:
  • MRI of Brain/Pituitary: If symptoms suggest CNS involvement (e.g., diabetes insipidus, neurological deficits).
  • Chest CT: If pulmonary symptoms or abnormalities on chest X-ray. Lung involvement is uncommon in isolated bone EG.

Management

Acute Management

• Immediate:
  • Pain Control: Oral or intravenous analgesics (NSAIDs, acetaminophen, opioids) as needed, tailored to pain severity.
  • Spinal Cord Compression: For suspected or confirmed spinal cord compression (e.g., from vertebral collapse), immediate neurological assessment, high-dose corticosteroids (e.g., dexamethasone 10 mg IV bolus then 4 mg IV q6h), and urgent surgical decompression or radiation therapy are warranted to prevent irreversible neurological damage.
  • Pathological Fracture: Immobilization and orthopedic consultation for stabilization (casting, bracing, or surgical fixation) to prevent further displacement or injury.
• Stabilization:
  • Biopsy: Obtain a biopsy for definitive diagnosis as soon as the patient is stable and necessary initial interventions are performed.
  • Consultations: Engage orthopedic surgeons, neurosurgeons (for spinal/cranial lesions), interventional radiologists, and hematologist/oncologists early in the diagnostic and management process.
• Emergency:
  • Airway Compromise: Rarely, lesions in the temporal bone or skull base can extend to compromise the airway, requiring emergency intubation or tracheostomy.
  • Severe Neurological Deficit: Rapid progression of weakness or sensory loss requires immediate surgical intervention to relieve compression.

Chronic Management

The management of eosinophilic granuloma primarily depends on the number and location of lesions, symptoms, and potential for complications. For unifocal bony EG, a conservative approach is often preferred due to its benign course and high rate of spontaneous resolution.

• Pharmacological:
  • Observation/Conservative Management: For asymptomatic, stable, or resolving lesions, particularly in non-weight-bearing bones, observation with serial imaging is often sufficient. Many unifocal EG lesions regress spontaneously within months to years.
  • Intralesional Corticosteroids:
    • Indication: Symptomatic solitary bone lesions, especially in the spine, skull, or accessible long bones, where surgical intervention is undesirable or high-risk.
    • Agent: Methylprednisolone acetate (e.g., 40-80 mg per lesion, depending on size).
    • Administration: Injected directly into the lesion under fluoroscopic or CT guidance.
    • Efficacy: Highly effective in reducing pain and promoting healing in a significant number of cases (reported success rates >70%). Can be repeated if necessary.
  • Low-Dose Radiation Therapy (XRT):
    • Indication: Reserved for symptomatic, unresponsive, or critical lesions (e.g., spine, orbit, weight-bearing bones) where surgical curettage is not feasible, or intralesional steroids have failed.
    • Dosage: Low doses are highly effective, typically 5-10 Gy (total) in 1-2 Gy fractions. Higher doses are usually unnecessary and increase long-term risks (e.g., secondary malignancy, growth retardation in children).
    • Considerations: Avoid in very young children if possible due to potential effects on bone growth and increased risk of malignancy.
  • Systemic Chemotherapy:
    • Indication: Generally not used for solitary or multifocal bone-only EG, unless there is widespread multifocal bone involvement, recurrence, progression despite local therapy, or suspicion of high-risk multisystem LCH.
    • Regimen (for LCH requiring systemic therapy): Often involves vinblastine (e.g., 6 mg/m² IV weekly for 6-12 weeks, then bi-weekly) and oral prednisone (e.g., 40 mg/m² daily for 4-6 weeks, then taper). Duration can be 6-12 months.
    • Targeted Therapy: For BRAF V600E-mutated LCH refractory to standard chemotherapy, BRAF inhibitors (e.g., vemurafenib, dabrafenib) or MEK inhibitors (e.g., trametinib) are emerging options, but are primarily for disseminated or refractory disease, not typically for isolated EG.
• Non-pharmacological:
  • Surgical Curettage (with or without bone grafting):
    • Indication: For symptomatic, accessible bone lesions that are easily amenable to surgery, particularly those with impending pathological fracture or those requiring tissue for diagnosis.
    • Procedure: Involves removal of the abnormal tissue from the bone defect. Can be combined with bone grafting (autograft or allograft) to fill the defect and promote healing, especially in weight-bearing bones.
    • Efficacy: Often curative, providing immediate symptomatic relief and definitive diagnosis.
  • Physical Therapy/Occupational Therapy: For rehabilitation after pathological fracture, spinal involvement, or surgery, to regain strength, mobility, and function.
  • Bracing/Immobilization: For pathological fractures or spinal instability, to provide support and promote healing.
• Monitoring:
  • Clinical Follow-up: Regular visits to assess symptoms (pain, swelling), neurological status, and overall well-being.
  • Serial Imaging: Repeat X-rays, CT, or MRI at regular intervals (e.g., every 3-6 months initially, then annually) to monitor lesion resolution, detect recurrence, or identify new lesions. Lesion healing is characterized by sclerotic changes and bone remodeling.
  • Bone Scan/PET-CT: May be repeated if there's suspicion of new lesions or progression.

Treatment Algorithms

• First-Line:
  1. Definitive Biopsy: Essential for diagnosis.
  2. Asymptomatic/Stable Lesions: Observation with serial imaging (X-rays) every 3-6 months.
  3. Symptomatic Lesions (accessible):
     • Surgical Curettage: For accessible lesions, especially those with impending fracture or if definitive diagnosis/resection is desired.
     • Intralesional Corticosteroid Injection: For accessible lesions where surgery is not preferred or feasible (e.g., spine, skull, or multiple lesions in a single site).
• Second-Line:
  1. Symptomatic Lesions refractory to first-line local therapy:
     • Low-Dose Radiation Therapy (XRT): For lesions unresponsive to steroids or curettage, or in critical locations (e.g., spine, orbit) where surgery is too risky.
     • Repeat Intralesional Steroid Injection: If initially effective but symptoms recur.
• Refractory Cases:
  • Progression or New Lesions (Multifocal Bone-Only LCH): If multiple bone lesions develop or a single lesion progresses despite local therapies, systemic evaluation (including a new bone scan/PET-CT and review of systems for systemic involvement) and consideration of systemic chemotherapy (e.g., vinblastine/prednisone) in consultation with a histiocytosis specialist.
  • BRAF-mutated refractory LCH: Consider targeted therapy with BRAF inhibitors, though less common for isolated EG.

Complications

• Common:
  • Pathological Fractures: Due to extensive bone lysis, especially in weight-bearing bones or long bones.
  • Persistent Pain: Despite treatment, some patients may experience chronic pain.
  • Cosmetic Deformity: Particularly with skull lesions or extensive bone loss.
• Serious:
  • Spinal Cord Compression: From vertebral collapse (vertebra plana) or epidural extension of the lesion, leading to myelopathy, cauda equina syndrome, or radiculopathy. This is a medical emergency.
  • Neurological Deficits: Cranial nerve palsies, proptosis (orbital lesions), hearing loss (temporal bone lesions).
  • Diabetes Insipidus: While more common in multisystem LCH with pituitary involvement, it can rarely occur with isolated skull base lesions.
  • Secondary Malignancy: A rare, long-term risk of radiation therapy, particularly with higher doses or in younger patients.
• Long-term:
  • Skeletal Deformities: Scoliosis, kyphosis, limb length discrepancy.
  • Recurrence: Local recurrence can occur, especially if the lesion is not completely excised or treated.
  • Progression to Multisystem LCH: Rare, but isolated EG can, in very few cases, evolve into multisystem disease.

Prognosis

• Factors:
  • Number of lesions: Unifocal EG has an excellent prognosis. Multifocal bone-only LCH also generally has a good prognosis.
  • Location: Lesions in critical areas (e.g., spine, skull base) have a higher risk of complications but generally do not worsen the overall prognosis for survival if managed appropriately.
  • Age: Younger age (especially <2 years) at diagnosis is generally associated with a higher risk of multifocal or multisystem disease, though isolated EG in this age group still has a good outcome.
  • Treatment response: Favorable response to local therapy or spontaneous resolution predicts an excellent outcome.
• Survival:
  • Excellent: The vast majority (over 95-99%) of patients with unifocal or multifocal bone-only eosinophilic granuloma have a favorable prognosis with complete resolution and no mortality directly attributed to the disease.
  • Morbidity: Morbidity is usually related to local complications such as pathological fractures, pain, or neurological deficits, rather than systemic progression.
• Quality of Life: Most patients achieve full functional recovery and have a normal quality of life following successful treatment. Careful follow-up is important to address potential late effects, particularly in children.

Prevention

• Primary: Currently, there are no known primary prevention strategies for eosinophilic granuloma, as its etiology is not fully understood.
• Secondary:
  • Early Diagnosis: Prompt diagnosis and appropriate management can prevent complications such as pathological fractures, severe pain, and neurological damage.
  • Comprehensive Staging: In a newly diagnosed case of EG, a thorough workup to rule out additional lesions (e.g., bone scan or PET-CT, physical exam for skin/lymph nodes, careful history for systemic symptoms) is crucial to ensure it truly is unifocal or multifocal bone-only, and not part of a broader multisystem LCH which requires different management.
• Tertiary:
  • Monitoring for Recurrence: Regular clinical and imaging follow-up to detect local recurrence or the development of new lesions early.
  • Rehabilitation: Aggressive physical and occupational therapy to optimize functional recovery and minimize long-term disability following fractures or spinal involvement.
  • Minimizing Treatment-Related Morbidity: Using the lowest effective dose of radiation, avoiding unnecessary surgery, and judicious use of systemic therapy to prevent complications.

Special Populations

• Pediatric:
  • Prevalence: Most common in children and adolescents.
  • Growth Plate Involvement: Lesions near growth plates can potentially lead to growth disturbances or limb length discrepancies, requiring careful monitoring and consideration of treatment modalities that spare growth plates where possible (e.g., intralesional steroids over extensive surgery or high-dose radiation).
  • Vertebra Plana: Vertebral involvement in children often leads to vertebra plana, but remarkable remodeling and height restoration often occur spontaneously or with conservative treatment, usually not requiring surgical intervention unless there is neurological compromise.
  • Radiation: Radiation therapy should be used cautiously in children due to the increased risk of secondary malignancies and growth impairment.
• Geriatric:
  • Rarity: EG is rare in the elderly. When it occurs, it may be more difficult to distinguish from other lytic bone lesions, including metastases or primary bone tumors.
  • Comorbidities: Management needs to consider pre-existing medical conditions, polypharmacy, and potential for treatment interactions.
  • Fracture Risk: Higher risk of pathological fractures due to underlying osteoporosis.
• Pregnancy:
  • Diagnosis: Imaging during pregnancy should minimize radiation exposure. MRI is generally preferred over CT. Biopsy is still essential but may require specific planning.
  • Treatment: Avoid radiation therapy during pregnancy. Intralesional corticosteroids may be considered if absolutely necessary, but generally, conservative management or surgical options should be prioritized. Systemic chemotherapy is generally contraindicated.
• Comorbidities:
  • Immunocompromised Patients: While EG is not a primary immunodeficiency, the immune response is involved. Care must be taken with steroid use in patients who are already immunocompromised.
  • Coagulopathy: Increases the risk of bleeding during biopsy or surgical procedures.
  • Metabolic Bone Disease: May exacerbate the risk of pathological fractures.

Clinical Pearls

• Diagnostic:
  • "Great Mimicker": EG can mimic various conditions, including osteomyelitis, Ewing sarcoma, osteosarcoma, and metastatic disease. Biopsy is always required for definitive diagnosis.
  • Birbeck Granules: Presence of Birbeck granules on electron microscopy is pathognomonic but often not necessary if IHC (CD1a, S100, Langerin) is conclusive.
  • Vertebra Plana: While characteristic of LCH, it can also be seen in metastatic disease, infection, or trauma.
  • BRAF Testing: Increasingly important, especially if disease is recurrent, multifocal, or requires systemic therapy, as it can guide targeted treatment.
• Treatment:
  • Local is Key: For unifocal EG, local therapies (observation, intralesional steroids, curettage, low-dose radiation) are usually curative. Avoid aggressive systemic therapy unless clearly indicated for disseminated LCH.
  • Spinal Lesions: Always assess for neurological compromise. If present, urgent neurosurgical consultation is paramount. However, many vertebral lesions, even with collapse, can be managed conservatively with good outcomes.
  • Radiation Dosing: If radiation is used, low doses (5-10 Gy) are highly effective and reduce long-term risks.
  • Spontaneous Regression: Many lesions, especially in children, can spontaneously regress, supporting a watchful waiting approach for asymptomatic, non-critical lesions.
• Pitfalls:
  • Misdiagnosis: Misinterpreting EG as a malignant tumor or infection, leading to unnecessary aggressive therapy.
  • Inadequate Staging: Failure to thoroughly evaluate for additional lesions or systemic involvement, leading to undertreatment of multifocal or multisystem LCH.
  • Overuse of Radiation: Administering high doses of radiation, especially in children, increasing the risk of secondary malignancies and growth disturbances.
  • Ignoring Neurological Symptoms: Delaying intervention for spinal cord compression, leading to irreversible neurological deficits.

Recent Updates

• Guidelines: The Histiocyte Society regularly updates its diagnostic and treatment guidelines for LCH, emphasizing risk stratification and tailored therapy. The 2018 Histiocyte Society guidelines provide comprehensive recommendations for LCH management.
• Evidence:
  • Molecular Understanding: Increased understanding of the genetic mutations (BRAF V600E, MAP2K1, etc.) driving LCH pathogenesis has led to the development of targeted therapies.
  • Targeted Therapies: While primarily for multisystem, high-risk, or refractory LCH, BRAF inhibitors (e.g., vemurafenib, dabrafenib) have shown promising results in BRAF V600E-mutated LCH. Their role in isolated EG is minimal unless it progresses to refractory or disseminated disease.
  • Role of PET-CT: Growing evidence supports the utility of FDG-PET/CT for staging and assessing disease activity, particularly for multifocal or multisystem LCH.
• Controversies:
  • Optimal Initial Management of Asymptomatic Lesions: The balance between observation vs. early intervention (e.g., intralesional steroids) for asymptomatic or mildly symptomatic EG lesions remains a topic of debate, with proponents for both approaches given the potential for spontaneous resolution.
  • Role of BRAF Testing in Unifocal EG: While BRAF testing is crucial for disseminated disease, its routine utility in truly unifocal EG is less clear, as these lesions rarely require systemic therapy. However, its detection can confirm clonality and provide potential options if the disease progresses.

Key References

• Guidelines:
  • Histiocyte Society LCH Guidelines: (e.g., Primary Therapy for Langerhans Cell Histiocytosis: A Report From the Histiocyte Society II. J Clin Oncol. 2009;27(30):5154-5161, and subsequent updates).
• Studies:
  • Héritier S, et al. LCH-IV: a multicentre, international, open-label, randomized, phase 3 trial to evaluate the efficacy of cytarabine and cladribine in Langerhans cell histiocytosis. Lancet Oncol. 2021;22(2):167-177. (While focused on systemic therapy, this illustrates the ongoing research in LCH).
  • Badalian-Very G, et al. BRAF V600E mutation in Langerhans cell histiocytosis. Blood. 2010;116(11):1919-1923. (Landmark study identifying the BRAF mutation).
  • Meyer JS, et al. Intralesional corticosteroid injection for solitary eosinophilic granuloma of bone: a review of the literature. Clin Orthop Relat Res. 2012;470(11):3266-3273. (Review on efficacy of intralesional steroids).
• Reviews:
  • Haupt R, et al. Langerhans Cell Histiocytosis: Current Treatment and Future Perspectives. Front Oncol. 2022;12:870701.
  • Donadieu J, et al. Langerhans cell histiocytosis. Lancet. 2012;379(9828):1942-1951.